SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a provider of personalized diagnostic services, announced today at the ASH Meeting in Atlanta, Georgia, that it will launch testing for the MPL W515 L/K mutation. This new test further expands the Genoptix service offering for patients with hematomalignancies, or cancers of the blood, to improve diagnosis and management. Genoptix believes it will be the first commercial hematology/oncology laboratory service provider to offer this test.
"Our ability to bring cutting-edge technologies to our physician partners, like both quantitative JAK2 and MPL testing, furthers our commitment to shepherding academic medicine to community-based practices," noted Tina Nova, Ph.D., President and CEO of Genoptix. Mike Nerenberg, M.D., Vice President of Business Development for Genoptix said, "MPL mutation analysis provides the hematologist/oncologist with a new diagnostic tool in the identification and management of myeloproliferative disorders, or MPD, a disease group that is becoming better understood with the availability of molecular assays such as this one."
MPL mutations, which affect the thrombopoietin receptor and result in the continuous activation of Janus 2 kinase (JAK2) and other pathways, are commonly associated with two myeloproliferative disorders, namely idiopathic myelofibrosis (IMF) and essential thrombocythemia (ET). MPL W515 L/K mutation analysis may be particularly useful for patients with suspected MPD that are negative for JAK2 mutations.
Genoptix utilizes Invader Plus(R) technology to achieve specific and sensitive detection of the MPL mutation.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to the launch and effectiveness of new tests, such as MPL W515 L/K mutation analysis, the utility of these tests as diagnostic tools, and the ability of Genoptix to bring new technologies and further expand its diagnostic services to its customers. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. These risks and uncertainties include risks that may affect Genoptix business operations, including changes in reimbursement levels, changes in regulations, payor policies or contracting arrangements with payors, increased competition, the limited operating history of Genoptix, dependence on Cartesian Medical Group for the provision of medical services, difficulties in managing its growth, and numerous regulatory and compliance risks, including compliance with governmental payor regulations and compliance with rules and regulations in California and other states. For information about risks and uncertainties that Genoptix faces, please refer to the risk factors section of the final prospectus from the Genoptix initial public offering filed with the United States Securities and Exchange Commission on October 30, 2007, as well as other subsequent filings with the Securities and Exchange Commission. Genoptix assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement.
Invader Plus(R) is a registered mark of Third Wave Technologies, Inc.
|SOURCE Genoptix, Inc.|
Copyright©2007 PR Newswire.
All rights reserved